Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 83,792 shares at $40.10 ($3.4M) on 2022-01-10, disclosed to the SEC on 2022-01-11.
Seasonal sale ($3.4M) by Chairman, President & CEO — this insider has traded ITCI in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.10 | 8,954 | $359K | 10.5% |
| 2 | $40.10 | 8,954 | $359K | 10.5% |
| 3 | $40.80 | 27,138 | $1.1M | 32.4% |
| 4 | $40.80 | 27,138 | $1.1M | 32.4% |
| 5 | $41.72 | 5,804 | $242K | 7.1% |
| 6 | $41.72 | 5,804 |
| $242K |
| 7.1% |
| Total | $40.78 avg | 83,792 | $3.4M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |